8 January 2026
VBB advises Adjuvant Global Health Technologies on investment in Phoenix Biosciences
1 min read
VBB has advised private investment fund Adjuvant Global Health Technologies (Adjuvant) on its investment in Phoenix Biosciences.
In the context of the Belgian pre-pack bankruptcy procedure relating to the distressed Univercells group, new corporate vehicle Phoenix Biosciences has acquired certain assets of Univercells subsidiary Quantoom Biosciences, a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics.
Adjuvant was a shareholder in the Univercells group and, alongside fellow shareholders, has contributed to a capital raise for Phoenix Biosciences.
The VBB team comprised partner Caroline DAOUT, counsel Virginie Lescot and associate Jens Westerwoudt.
->
News & insights
3 min
read
read
Briefings
Belgian Competition Authority Orders AutoScout24 to Restore Data Portability to Competing Platform Subject to Penalty Payments
5 May 2026
1 min
read
read
Briefings
European Commission issues new draft merger control guidelines, launches public consultation
30 April 2026
1 min
read
read
Briefings
First CMA Consumer Fine Shows Commitment to Enforce New Regime
29 April 2026
1 min
read
read
Briefings
EU circular economy package: short-term measures targeting plastics crisis and market distortions
29 April 2026
1 min
read
read
Briefings
EU Commission disqualifies Chinese supplier in its first FSR procurement decision
28 April 2026
2 min
read
read
Briefings
Belgian Competition Authority Publishes Guidelines on Sustainability Agreements
7 April 2026
1 min
read
read
Briefings
Court of Justice of European Union Clarifies Scope of Officinal Formula Exemption Under EU Medicinal Product Law
25 March 2026
3 min
read
read
Briefings
UK CMA Concludes Veterinary Sector Market Investigation and Announces Major Reforms
24 March 2026
